Document is current
Any future updates will be listed below
-
Authors
Menzies-Gow, Andrew
Ambrose, Christopher S.
Colice, Gene
Hunter, Gillian
Cook, Bill
Molfino, Nestor A.
Llanos, Jean-Pierre
Israel, Elliot
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03347279 at ClinicalTrials.govDocuments that mention this clinical trial
M23 Efficacy of tezepelumab in patients with severe, uncontrolled asthma by prior omalizumab use: a post hoc analysis of the phase 3 NAVIGATOR study
https://doi.org/10.1136/thorax-2023-btsabstracts.412
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study
https://doi.org/10.1007/s12325-024-02889-8
S119 Effect of tezepelumab in patients with severe, uncontrolled asthma by age of onset, allergic status, and eosinophilic phenotype
https://doi.org/10.1136/thorax-2023-btsabstracts.125
S48 Efficacy of tezepelumab according to age at asthma onset in NAVIGATOR
https://doi.org/10.1136/thorax-2022-btsabstracts.54
M26 The proportion of patients achieving low biomarker levels with tezepelumab treatment in the phase 3 NAVIGATOR study
https://doi.org/10.1136/thorax-2023-btsabstracts.415
S65 Tezepelumab reduced OCS use in OCS-dependent patients with severe asthma: phase 3b WAYFINDER study interim results
https://doi.org/10.1136/thorax-2023-btsabstracts.71
S49 Effect of tezepelumab on a composite of severe asthma exacerbations and acute worsening events, CompEx, in the phase 3 NAVIGATOR study
https://doi.org/10.1136/thorax-2022-btsabstracts.55
P202 On-treatment clinical remission with tezepelumab in OCS-dependent patients with severe asthma in WAYFINDER
https://doi.org/10.1136/thorax-2025-btsabstracts.383
S47 DESTINATION: tezepelumab long-term safety and efficacy versus placebo in patients with severe, uncontrolled asthma
https://doi.org/10.1136/thorax-2022-btsabstracts.53
P22 Biomarkers and phenotyping: a holistic approach to asthma treatment with tezepelumab
https://doi.org/10.1136/thorax-2024-btsabstracts.183
M21 On-treatment clinical remission with tezepelumab in patients with severe, uncontrolled asthma in the phase 3 DESTINATION study
https://doi.org/10.1136/thorax-2023-btsabstracts.410
S67 Biomarkers and clinical outcomes after cessation of tezepelumab after 2 years of treatment (DESTINATION)
https://doi.org/10.1136/thorax-2023-btsabstracts.73
Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study
https://doi.org/10.1007/s12325-023-02659-y
P23 Asthma exacerbation rates as a function of biomarker levels 4 weeks after initiation of tezepelumab treatment: an analysis of the NAVIGATOR study
https://doi.org/10.1136/thorax-2024-btsabstracts.184
-
Funding
Funding for this research was provided by:
AstraZeneca
Amgen
- License Information
-
More Information
Article History
Received: 4 April 2023
Accepted: 21 August 2023
First Online: 19 September 2023
Declarations
:
: Andrew Menzies-Gow has a new and additional affiliation of Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK; is an employee of AstraZeneca and has attended advisory board meetings for AstraZeneca, GSK, Novartis, Regeneron, Sanofi, and Teva Pharmaceuticals; has received speaker fees from AstraZeneca, Novartis, Sanofi, and Teva Pharmaceuticals; has participated in research with AstraZeneca, for which his institution has been remunerated; has attended international conferences with Teva Pharmaceuticals; and has consultancy agreements with AstraZeneca and Sanofi. Christopher S. Ambrose, Gene Colice, Gillian Hunter, and Bill Cook are employees of AstraZeneca and may own stock or stock options in AstraZeneca. Nestor A. Molfino and Jean-Pierre Llanos are employees of Amgen and own stock in Amgen. Elliot Israel has served as a consultant to and received personal fees from 4D Pharma, AB Science, Amgen, AstraZeneca, Avillion, Biometry, Cowen, Equillium, Genentech, GSK, Merck, Novartis, Pneuma Respiratory, PPS Health, Regeneron Pharmaceuticals, Sanofi, Sienna Biopharmaceuticals, and Teva Pharmaceuticals; has received nonfinancial support from Circassia, Teva Pharmaceuticals, and Vorso Corp; and has received clinical research grants from AstraZeneca, Avillion, Genentech, Gossamer Bio, Novartis, and Sanofi.
: The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice guidelines and applicable regulatory requirements. Approvals from the Copernicus Central Institutional Review Board (Cary, NC, USA) and local independent ethics committees were obtained, and all patients or their guardians provided written informed consent in accordance with local requirements.
